Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This review outlines the various adverse reactions to biologic therapies in Allergy/Immunology, emphasizing the clinical and management challenges due to overlapping reaction phenotypes and the need for more refined diagnostic and management strategies.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This study reported that a novel filler, BM-PHA, demonstrated similar efficacy and safety to Restylane Perlane in treating moderate to severe nasolabial folds over 24 weeks, showing only minor local side effects and similar improvements in wrinkle severity scores between the two treatments.

Systemic mastocytosis may cause a type of hair loss called cicatricial alopecia.

The researchers reported that the novel MBTPS2 variant p.Glu172Asp found in a male proband is likely pathogenic, consistent with osteogenesis imperfecta symptoms and molecular signatures, including disrupted fatty acid metabolism and collagen production.

In this retrospective case series, baricitinib showed effectiveness in treating alopecia areata, with some potential benefits for psoriasis, but it may not be suitable for managing psoriatic arthritis in patients with these coexisting conditions.

This study explored using large language models to automatically identify monkeypox cases from electronic medical records, finding that models based on DeepSeek features performed better than traditional methods, with logistic regression showing high accuracy in detecting key symptoms like fever and rash.

This case report documented a 74-year-old female with alopecic patches and other skin issues during talquetamab therapy for multiple myeloma, suggesting that the drug may cause skin-related adverse effects due to reactivity to GPRC5D-expressing structures.

In this study, several photobiomodulation devices showed statistically significant improvement in hair growth for patients with androgenetic alopecia, with varying efficacy between devices and genders.

This study found that females exposed to high cumulative doses of cyproterone acetate had a 6–20 fold increased risk of developing meningiomas compared to those on lower doses.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study found that patients with Bachmann-Bupp syndrome treated with DFMO showed improvements in hair growth, muscle tone, and development.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

In this report, a 25-year-old female patient with anti-MDA5 antibody-positive dermatomyositis and alopecia areata achieved complete remission of hair loss after treatment with baricitinib.

This study found that drug adherence rates in men with benign prostatic hyperplasia were low, decreasing with longer treatment duration, and were higher in patients with more severe symptoms.

This study concluded that antimullerian hormone levels are not generally effective for distinguishing late onset congenital adrenal hyperplasia from all hyperandrogenic polycystic ovary syndrome subtypes, except one specific subtype.

In this study, the choice between Belimumab and Anifrolumab for treating Systemic Lupus Erythematosus was mainly influenced by the clinical features of the disease, such as chronic-active or relapsing-remitting courses and specific manifestations like cutaneous involvement or arthritis.

In this cross-sectional study, researchers found no significant difference in effectiveness between paclitaxel-carboplatin and pemetrexed-carboplatin for treating pulmonary adenocarcinoma with negative EGFR mutations, but paclitaxel-carboplatin was more cost-effective and associated with more frequent severe haematological toxicities.

This study found that patients with alopecia areata have significantly higher medication adherence than those with atopic dermatitis, potentially due to the stability and controllability of alopecia areata symptoms.

In these initial clinical studies, NAP monotherapy showed significant reductions in HBsAg levels among patients with chronic HBV, suggesting potential as part of future combination therapies.

This study found that sinapic acid promotes the browning of 3T3-L1 adipocytes and may offer therapeutic potential for obesity by influencing mitochondrial biogenesis through the p38 MAPK/CREB signaling pathway.

This review discusses evidence that regular physical activity and tailored dietary interventions improve metabolic health in women with PMOS, advocating for personalized lifestyle management in their care, and reports no new clinical results.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

In this study, FemmeBalance significantly alleviated several PMS symptoms, including physical discomfort and mood disturbance, while also enhancing skin health and social functioning, suggesting it might serve as a viable alternative to traditional PMS treatments.

This study concluded that intramuscular administration of medium-dose cyproterone acetate with oral ethinylestradiol is highly effective in managing hirsutism, showing better response rates than high-dose oral treatment.

In this randomized controlled trial, PRP combined with redensyl, saw palmetto, and biotin showed superior efficacy in improving androgenetic alopecia grading scores in male patients when compared to PRP with Procapil.

This review outlines strategies for preventing, identifying, and managing complications related to current MS therapies and reports no new clinical results, emphasizing the growing complexity in MS treatment regimens.

In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.